Literature DB >> 10580202

Vaccination of infants with a four-dose and a three-dose vaccination schedule.

J Taranger1, B Trollfors, N Knutsson, V Sundh, T Lagergård, E Ostergaard.   

Abstract

Swedish infants were vaccinated with diphtheria, tetanus and pertussis toxoids, inactivated poliovirus vaccine and a Haemophilus influenzae type b - tetanus toxoid conjugate vaccine at 2, 4, 6 and 15 months (US vaccination program, 'US arm', n=118) or at 3, 5 and 12 months of age (Swedish vaccination program, 'Swedish arm', n=103). The antigen amounts in the diphtheria and tetanus vaccines were higher in the Swedish than in the US arm while the amounts in the other vaccines were the same in both arms. There were no serious side effects. Local reactions increased with the numbers of doses but did not differ significantly between the groups. Serum was obtained at 2, 7, 15 and 16 months in the US arm and at 3, 6, 12 and 13 months of age in the Swedish arm. A fifth serum was obtained in both groups at 4 yr of age. For vaccines with the same antigen amount the following was observed: a. three doses at 2, 4 and 6 months were more immunogenic than two doses at 3 and 5 months; b. the third dose in the Swedish arm was more immunogenic than the third dose in the US arm; c. the fourth dose in the US arm induced higher antibodies than the third dose in the Swedish arm (except for pertussis toxin antibodies that were similar in both groups) and the differences tended to remain at the age of 4 yr. Children in the Swedish arm received a higher diphtheria toxoid dose (25 Lf) than in the US arm (15 Lf) which led to higher diphtheria toxin antibodies in the Swedish arm at comparable ages. Children in the Swedish arm received a higher tetanus toxoid dose (7 Lf) than in the US arm (6 Lf). Tetanus antibodies were similar at comparable ages. In conclusion, the immunogenicity of vaccines in infancy can be improved by increasing the number of doses, by prolonging the intervals between doses and by increasing the antigen amount in the vaccine.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10580202     DOI: 10.1016/s0264-410x(99)00341-2

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  The pertussis enigma: reconciling epidemiology, immunology and evolution.

Authors:  Matthieu Domenech de Cellès; Felicia M G Magpantay; Aaron A King; Pejman Rohani
Journal:  Proc Biol Sci       Date:  2016-01-13       Impact factor: 5.349

2.  Diphtheria, tetanus and pertussis antibodies in 10-year-old children before and after a booster dose of three toxoids: implications for the timing of a booster dose.

Authors:  Birger Trollfors; Nina Knutsson; John Taranger; Anders Mark; Elisabet Bergfors; Valter Sundh; Teresa Lagergård
Journal:  Eur J Pediatr       Date:  2005-10-26       Impact factor: 3.183

3.  Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines.

Authors:  Andrew J Pollard; Kirsten P Perrett; Peter C Beverley
Journal:  Nat Rev Immunol       Date:  2009-03       Impact factor: 53.106

4.  A Phase 1 study of the blood-stage malaria vaccine candidate AMA1-C1/Alhydrogel with CPG 7909, using two different formulations and dosing intervals.

Authors:  Ruth D Ellis; Gregory E D Mullen; Mark Pierce; Laura B Martin; Kazutoyo Miura; Michael P Fay; Carole A Long; Donna Shaffer; Allan Saul; Louis H Miller; Anna P Durbin
Journal:  Vaccine       Date:  2009-05-15       Impact factor: 3.641

5.  How French physicians manage with a future change in the primary vaccination of infants against diphtheria, tetanus, pertussis and poliomyelitis? A qualitative study with focus groups.

Authors:  Karine Lungarde; Fanette Blaizeau; Isabelle Auger-Aubin; Daniel Floret; Serge Gilberg; Christine Jestin; Thomas Hanslik; Corinne Le Goaster; Daniel Lévy-Bruhl; Thierry Blanchon; Louise Rossignol
Journal:  BMC Fam Pract       Date:  2013-06-19       Impact factor: 2.497

Review 6.  Perplexities of pertussis: recent global epidemiological trends and their potential causes.

Authors:  D W Jackson; Pejman Rohani
Journal:  Epidemiol Infect       Date:  2013-01-16       Impact factor: 4.434

Review 7.  Combined hexavalent diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated poliovirus-Haemophilus influenzae type B vaccine; Infanrix™ hexa: twelve years of experience in Italy.

Authors:  Vincenzo Baldo; Paolo Bonanni; Marcela Castro; Giovanni Gabutti; Elisabetta Franco; Federico Marchetti; Rosa Prato; Francesco Vitale
Journal:  Hum Vaccin Immunother       Date:  2013-09-04       Impact factor: 3.452

8.  Immunological persistence in 5 y olds previously vaccinated with hexavalent DTPa-HBV-IPV/Hib at 3, 5, and 11 months of age.

Authors:  Sven A Silfverdal; Deepak Assudani; Sherine Kuriyakose; Olivier Van Der Meeren
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.